A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor can both promote and inhibit prostate cancer progression, depending on the ...
Approval was based on the positive outcomes of Lifyorli’s pivotal ROSELLA trial, which enrolled 381 patients with ...
A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor can both promote and inhibit prostate cancer progression, depending on the ...
Glucocorticoid receptors (GRs) are ligand-activated transcription factors that play a pivotal role in mediating the effects of endogenous and synthetic glucocorticoids. These receptors regulate a ...
Platinum-based chemotherapy is a standard treatment for ovarian cancer, but its effectiveness can be limited in some cases.
New research sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by limiting the ...
Drugs to treat inflammatory and autoimmune diseases - such as asthma, psoriasis, rheumatoid arthritis or Chrousos syndrome - act mainly through the glucocorticoid receptor (GR). This essential protein ...
These data were simultaneously published in The Lancet: “ Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised ...
Lifyorli competitively binds to the glucocorticoid receptor (GR), where it enhances chemotherapy sensitivity by inhibiting cortisol’s suppression of apoptosis – the programmed cell death that ...
Approval was based on the positive outcomes of Lifyorli’s pivotal ROSELLA trial, which enrolled 381 patients with platinum-resistant ovarian cancer who had received one to three prior lines of therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results